Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the likely reintroduction of Biogen Idec/Elan's Tysabri (natalizumab) in the United States, despite rare fatal side effects, is a testimony to the high unmet need for efficacious treatments against multiple sclerosis (MS).

The new Pharmacor report entitled Multiple Sclerosis finds that a recent recommendation by a U.S. Food and Drug Administration (FDA) advisory panel to relaunch Tysabri will result in the return of the drug to the U.S. market this summer and its launch in Europe by the end of 2006. Tysabri was voluntarily pulled from shelves by Biogen Idec/Elan earlier this year following rare fatal cases of progressive multifocal encephalopathy. The report also finds that, although the pipeline to treat MS is remarkably active, no blockbuster drugs are expected to emerge in the market through 2015.

"Although Tysabri will be a player in the market following its relaunch because of its significant efficacy, neurologists say they are uncomfortable administering this drug as a first-line therapy in light of the potentially fatal side-effects," said Andrea Witt, Ph.D., analyst at Decision Resources, Inc. "One physician indicated that he would prescribe Tysabri only to a patient in 'desperate straits' because of the risks associated with the drug. Based on these factors and other key findings, we forecast that neither Tysabri nor any emerging drug in the dynamic MS pipeline will become blockbusters in the next ten years."

About Multiple Sclerosis

Multiple sclerosis is a chronic inflammatory disease of the central nervous system. The disease affects more than 1 million people worldwide, including twice as many women as men. Most people first experience symptoms between ages 20 and 40.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    (781) 296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

With Meteoric Growth of the Prevalent Patient Population, the Mild Cognitive Impairment Drug Market Will Be at $1 Billion by 2014

View Now